| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
|
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | ||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
INFINITY PHARMACEUTICALS, INC. [ INFI ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 12/07/2012 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 12/07/2012 | M | 22,103 | A | $3.48 | 338,641 | D | |||
| Common Stock | 12/07/2012 | M | 331 | A | $3.48 | 338,972 | D | |||
| Common Stock | 12/07/2012 | M | 29,432 | A | $13.59 | 368,404 | D | |||
| Common Stock | 12/07/2012 | M | 10,204 | A | $9.8 | 378,608 | D | |||
| Common Stock | 12/07/2012 | M | 13,927 | A | $7.18 | 392,535 | D | |||
| Common Stock | 12/07/2012 | M | 23,070 | A | $6.25 | 415,605 | D | |||
| Common Stock | 12/07/2012 | M | 76,930 | A | $5.94 | 492,535 | D | |||
| Common Stock | 5,684.474(1) | I | 401(k) | |||||||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Stock Option (right to buy) | $3.48 | 12/07/2012 | M | 22,103 | (2) | 03/31/2016 | Common Stock | 22,103 | $0 | 0 | D | ||||
| Stock Option (right to buy) | $3.48 | 12/07/2012 | M | 331 | (3) | 03/31/2016 | Common Stock | 331 | $0 | 0 | D | ||||
| Stock Option (right to buy) | $13.59 | 12/07/2012 | M | 29,432 | (4) | 01/24/2017 | Common Stock | 29,432 | $0 | 0 | D | ||||
| Stock Option (right to buy) | $9.8 | 12/07/2012 | M | 10,204 | (5) | 12/13/2017 | Common Stock | 10,204 | $0 | 0 | D | ||||
| Stock Option (right to buy) | $7.18 | 12/07/2012 | M | 13,927 | (6) | 12/04/2018 | Common Stock | 13,927 | $0 | 0 | D | ||||
| Stock Option (right to buy) | $6.25 | 12/07/2012 | M | 23,070 | (7) | 01/05/2020 | Common Stock | 23,070 | $0 | 340,930 | D | ||||
| Stock Option (right to buy) | $5.94 | 12/07/2012 | M | 76,930 | (8) | 01/06/2021 | Common Stock | 76,930 | $0 | 83,620 | D | ||||
| Explanation of Responses: |
| 1. Represents shares of Infinity Pharmaceuticals, Inc. common stock acquired under the Infinity Pharmaceuticals, Inc. 401(k) plan. |
| 2. This option was fully vested with respect to all 22,103 shares subject to the option as of the date hereof. |
| 3. This option was fully vested with respect to all 331 shares subject to the option as of the date hereof. |
| 4. This option was fully vested with respect to all 29,432 shares remaining subject to the option as of the date hereof. |
| 5. This option was fully vested with respect to all 10,204 shares remaining subject to the option as of the date hereof. |
| 6. This option was fully vested with respect to all 13,927 shares remaining subject to the option as of the date hereof. |
| 7. This option was vested with respect to 265,416 shares as of the date hereof and vests as to 1/48th of the 364,000 shares subject to the initial option at the end of each calendar month. |
| 8. This option was vested with respect to 76,930 shares as of the date hereof and vests as to 1/48th of the 160,550 shares subject to the initial option at the end of each calendar month. |
| /s/Adelene Q. Perkins | 12/10/2012 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||